免疫功能抑制宿主脓毒症的临床特征与早期预警
该回顾性研究纳入滨州医学院附属医院ICU 2011年10月至2022年10月收治的169例脓毒症患者,按是否符合免疫功能抑制宿主诊断标准分为免疫功能抑制组(61例)与免疫正常组(108例)。免疫功能抑制组血流感染比例最高,革兰阴性菌感染率显著低于免疫正常组[49.2%(30/61)vs. 64.8%(70/108),P<0.05],革兰阳性菌[27.9%(17/61)vs. 13.9%(15/108)]及多重耐药菌[54.1%(33/61)vs. 29.6%(32/108)]感染率显著更高(均P<0.05),发热比例显著更低[49.2%(30/61)vs. 66.7%(72/108),P<0.05]。免疫功能抑制组中性粒细胞计数及百分比显著更低,淋巴细胞百分比、中性粒细胞/淋巴细胞比值(NLR)、C反应蛋白(CRP)、降钙素原(PCT)、APACHE II评分、合并休克率、免疫麻痹发生率及住院病死率显著更高。多因素Logistic回归显示NLR、CRP、PCT为免疫功能抑制脓毒症的独立危险因素(均P<0.05),据此构建回归方程Logit(P)=0.025X1+0.010X2+0.013X3-2.945(X1、X2、X3分别为NLR、CRP、PCT),Omnibus检验与Hosmer-Lemeshow检验显示模型拟合良好且具有一定早期预警价值。
要点
- 免疫功能抑制脓毒症患者发热比例显著低于免疫正常组[49.2%(30/61)vs. 66.7%(72/108),P<0.05],无发热不能排除脓毒症。
- 免疫功能抑制组多重耐药菌感染率显著高于免疫正常组[54.1%(33/61)vs. 29.6%(32/108),P<0.05],经验性抗菌药物需覆盖耐药菌。
- 免疫功能抑制组革兰阳性菌感染率显著高于免疫正常组[27.9%(17/61)vs. 13.9%(15/108),P<0.05]。
- NLR、CRP、PCT为免疫功能抑制脓毒症的独立危险因素(均P<0.05),回归方程Logit(P)=0.025X1+0.010X2+0.013X3-2.945可能具有早期预警意义。
- 免疫功能抑制组合并休克率、免疫麻痹发生率及住院病死率均显著高于免疫正常组。
适用人群与场景
- 滨州医学院附属医院ICU 2011年10月至2022年10月收治的脓毒症患者,共169例,其中免疫功能抑制组61例、免疫正常组108例。
- 按是否符合免疫功能抑制宿主诊断标准分组。
诊断标准与关键阈值
- 以是否符合免疫功能抑制宿主诊断标准分为免疫功能抑制组与免疫正常组。
- 回归方程Logit(P)=0.025X1+0.010X2+0.013X3-2.945,X1、X2、X3分别为NLR、CRP、PCT。
红旗征与不能漏的情况
- 免疫功能抑制脓毒症患者发热比例显著低于免疫正常组[49.2%(30/61)vs. 66.7%(72/108),P<0.05],发热不显著仍需警惕脓毒症。
- 免疫功能抑制组多重耐药菌感染率显著高于免疫正常组[54.1%(33/61)vs. 29.6%(32/108),P<0.05]。
- 免疫功能抑制组合并休克率、免疫麻痹发生率及住院病死率均显著高于免疫正常组。
研究设计与关键结果
- 回顾性研究,纳入169例脓毒症患者,免疫功能抑制组61例、免疫正常组108例。
- 免疫功能抑制组感染部位前3位为血流感染、肺部感染、腹腔感染;免疫正常组前3位为肺部感染、血流感染、腹腔感染。
- 革兰阴性菌感染率:免疫功能抑制组49.2%(30/61)vs. 免疫正常组64.8%(70/108),免疫功能抑制组显著更低(P<0.05)。
- 革兰阳性菌感染率:免疫功能抑制组27.9%(17/61)vs. 免疫正常组13.9%(15/108),免疫功能抑制组显著更高(P<0.05)。
- 多重耐药菌感染率:免疫功能抑制组54.1%(33/61)vs. 免疫正常组29.6%(32/108),免疫功能抑制组显著更高(P<0.05)。
- 发热比例:免疫功能抑制组49.2%(30/61)vs. 免疫正常组66.7%(72/108),免疫功能抑制组显著更低(P<0.05)。
- 免疫功能抑制组中性粒细胞计数及百分比显著低于免疫正常组,淋巴细胞百分比、NLR、CRP、PCT、APACHE II评分、合并休克率、免疫麻痹发生率及住院病死率显著高于免疫正常组。
- 多因素Logistic回归显示NLR、CRP、PCT为免疫功能抑制脓毒症的独立危险因素(均P<0.05),构建回归方程Logit(P)=0.025X1+0.010X2+0.013X3-2.945,Omnibus检验与Hosmer-Lemeshow检验显示模型拟合良好且具有一定早期预警价值。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为基于NLR、CRP、PCT构建的回归方程可能对免疫功能抑制脓毒症患者具有早期预警意义。
- 免疫功能抑制脓毒症患者发热比例显著更低,无发热时仍需按脓毒症评估。
- 免疫功能抑制脓毒症患者革兰阳性菌及多重耐药菌感染率显著更高,经验性抗菌治疗需考虑覆盖。
- 免疫功能抑制脓毒症患者合并休克率、免疫麻痹发生率及住院病死率显著更高,需加强监护。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the clinical features of the sepsis in immunocompromised hosts and establish an early warning equation.
METHODS: A retrospective study was conducted on sepsis patients admitted to the intensive care unit (ICU) of Binzhou Medical University Hospital from October 2011 to October 2022. General information, infection site, etiology results and drug susceptibility, clinical symptoms, inflammatory indicators, acute physiology and chronic health status evaluation II (APACHE II), sequential organ failure assessment (SOFA), incidence of immune paralysis, and outcome during hospitalization were collected. Based on whether they met the diagnostic criteria for immunocompromised hosts, patients were divided into immunocompromised group and immune normal group. The clinical information of the two groups were compared. Multivariate Logistic regression was used to analyze the risk factors of patients with immunocompromised sepsis and the regression equation model was initially established. Omnibus test and Hosmer-Lemeshow test were used to evaluate the model.
RESULTS: A total of 169 patients with sepsis were included, including 61 in the immunocompromised group and 108 in the normal immune group. The top 3 infection sites in the immunocompromised group were bloodstream infection, pulmonary infection and abdominal infection. The top 3 infection sites in the normal immune group were pulmonary infection, bloodstream infection and abdominal infection. The infection rate of Gram-negative bacteria in the immunocompromised group was significantly lower than that in the normal group [49.2% (30/61) vs. 64.8% (70/108), P < 0.05]. The infection rate of Gram-positive bacteria [27.9% (17/61) vs. 13.9% (15/108)] and multidrug-resistant bacteria [54.1% (33/61) vs. 29.6% (32/108)] were significantly higher than those in normal immune group (both P < 0.05). In terms of clinical symptoms, the proportion of fever in the immunocompromised group was significantly lower than that in the immune normal group [49.2% (30/61) vs. 66.7% (72/108), P < 0.05]. Neutrophil count (NEU) and neutrophil percentage (NEU%) in the immunocompromised group were significantly lower than those in the normal immune group. Lymphocyte percentage (LYM%), neutrophil/lymphocyte ratio (NLR), C-reactive protein (CRP), procalcitonin (PCT), APACHE II score, combined shock rate, incidence of immune paralysis, and mortality during hospitalization in the immunocompromised group were significantly higher than those in the normal immune group. Logistic regression analysis showed that NLR, CRP and PCT were risk factors for patients with immunocompromised sepsis (all P < 0.05). The above indicators were used as covariables to construct a Logistic regression equation, that was, Logit (P) = 0.025X1+0.010X2+0.013X3-2.945, where X1, X2 and X3 represent NLR, CRP and PCT respectively. Omnibus test and Hosmer-Lemeshow test show that the model fits well and has certain early warning value.
CONCLUSIONS: Patients with immunocompromised sepsis have more intense inflammatory response, with Gram-negative bacteria being the predominant pathogen, and a higher incidence of Gram-positive bacterial infections and multi-drug resistant infections. The severity of the disease, in-hospital mortality, the incidence of shock and the incidence of immune paralysis after sepsis were significantly higher. NLR, CRP and PCT were independent risk factors for sepsis in immunocompromised hosts. The regression equation constructed based on this may have early warning significance for patients with immunocompromised sepsis.
参考来源
- Chen Y, Guo R, Huang X, et al. [Clinical features and early warning of the sepsis in immunocompromised host sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40201994. doi:10.3760/cma.j.cn121430-20240729-00638
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。